Naftopidil
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
- Naftopidil
- Naftopidil: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita
Naftopidil: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita
One-Sentence Summary
Naftopidil is a selective α1-adrenergic receptor antagonist primarily approved in Japan for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). The TxGNN model predicts it may be effective for Ambras Type Hypertrichosis Universalis Congenita (an ultra-rare congenital hair disorder), however with 0 clinical trials and 0 publications currently supporting this direction, the evidence basis is entirely absent.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not registered in India (BPH / LUTS per Japan approval records) |
| Predicted New Indication | Ambras Type Hypertrichosis Universalis Congenita |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, Naftopidil belongs to the selective α1-adrenergic receptor antagonist class (with preferential affinity for α1D and α1A receptor subtypes). Its efficacy in BPH and lower urinary tract symptoms has been demonstrated in clinical practice, primarily in Japan, where it is approved and marketed.
Regarding the mechanistic connection to Ambras type hypertrichosis universalis congenita: α1-adrenergic receptors are indeed expressed in hair follicles, and noradrenergic signalling is known to theoretically influence follicular cycling — specifically the transition from the growth phase (anagen) to the regression phase (catagen). On this basis alone, the knowledge graph may have linked Naftopidil to hair-related disease nodes. However, Ambras type hypertrichosis universalis congenita is caused by structural mutations in the TRPS1 gene and affects fewer than 100 individuals globally. This is a structural genetic defect — not a receptor-mediated or inflammatory process — and α1-receptor antagonism has no established mechanism by which it could compensate for or reverse an underlying genomic transcription factor deficiency.
The high TxGNN prediction score most likely reflects co-localization of hair-related nodes within the knowledge graph rather than genuine biological plausibility. There is no preclinical, translational, or clinical evidence to support this repurposing hypothesis, and the mechanistic rationale is considered biologically implausible for this specific indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Naftopidil holds no product registrations in India. The drug is currently not approved, manufactured, or distributed in the Indian market. No authorization records exist in the regulatory database.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a very high TxGNN prediction score (99.96%), Ambras type hypertrichosis universalis congenita is a monogenic structural disorder caused by TRPS1 mutations, for which α1-adrenergic receptor antagonism has no scientifically plausible therapeutic mechanism. The prediction is likely an artefact of topological proximity within the knowledge graph, and no supporting clinical or preclinical evidence exists whatsoever.
To proceed, the following is needed:
- Formal mechanism of action documentation (MOA) to confirm receptor binding profile and pharmacodynamics
- Preclinical evidence — at minimum a cell or animal model — demonstrating any effect of α1-antagonism on TRPS1-related hair follicle pathology
- Independent biological rationale beyond knowledge graph co-occurrence
- India regulatory pathway assessment, as the drug is currently not registered and would require full NDA/import licensing before any clinical exploration
- Consideration of whether alternative, higher-ranked predictions with stronger mechanistic grounding (e.g., urological or vascular indications) offer more viable repurposing pathways for this compound
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.